BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 38711642)

  • 1. Distinguishing Tumor Cell Infiltration and Vasogenic Edema in the Peritumoral Region of Glioblastoma at the Voxel Level via Conventional MRI Sequences.
    He L; Zhang H; Li T; Yang J; Zhou Y; Wang J; Saidaer T; Liu X; Wang L; Wang Y
    Acad Radiol; 2024 Mar; 31(3):1082-1090. PubMed ID: 37689557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
    Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
    Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting glioblastoma recurrence using multiparametric MR imaging of non-enhancing peritumoral regions at baseline.
    Xing Z; Wang C; Yang W; She D; Yang X; Cao D
    Heliyon; 2024 May; 10(9):e30411. PubMed ID: 38711642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
    van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
    J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiating Glioblastoma from Primary Central Nervous System Lymphoma: The Value of Shaping and Nonenhancing Peritumoral Hyperintense Gyral Lesion on FLAIR Imaging.
    Wang P; Shi YH; Li JY; Zhang CZ
    World Neurosurg; 2021 May; 149():e696-e704. PubMed ID: 33548537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma.
    Nael K; Bauer AH; Hormigo A; Lemole M; Germano IM; Puig J; Stea B
    AJR Am J Roentgenol; 2018 Jan; 210(1):18-23. PubMed ID: 28952810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
    Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
    J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local Fractional Anisotropy Is Reduced in Areas with Tumor Recurrence in Glioblastoma.
    Bette S; Huber T; Gempt J; Boeckh-Behrens T; Wiestler B; Kehl V; Ringel F; Meyer B; Zimmer C; Kirschke JS
    Radiology; 2017 May; 283(2):499-507. PubMed ID: 28234549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin.
    Bennett IE; Field KM; Hovens CM; Moffat BA; Rosenthal MA; Drummond K; Kaye AH; Morokoff AP
    J Neurooncol; 2017 Jan; 131(2):321-329. PubMed ID: 27896520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Glioblastoma Recurrence by Early Changes in the Apparent Diffusion Coefficient Value and Signal Intensity on FLAIR Images.
    Chang PD; Chow DS; Yang PH; Filippi CG; Lignelli A
    AJR Am J Roentgenol; 2017 Jan; 208(1):57-65. PubMed ID: 27726412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy.
    Singh R; Kesavabhotla K; Kishore SA; Zhou Z; Tsiouris AJ; Filippi CG; Boockvar JA; Kovanlikaya I
    AJNR Am J Neuroradiol; 2016 Oct; 37(10):1838-1843. PubMed ID: 27231225
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.